Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. Apple Notes is available to you if you buy an iPhone, iPad, or Mac ...

Arkansas is changing fast, and we’re here to help you make sense of it. Sign up today and receive the news that's important to you straight to your inbox. We’re here to hold power accountable, but we ...

Google’s NotebookLM is experimenting with a feature that could make studying feel a lot more like attending an actual class. A new Lecture mode can turn your uploaded notes, documents, and sources ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

This is read by an automated voice. Please report any issues or inconsistencies here. On a nippy Monday night at the Zebulon in Frogtown, a man wearing a Jason Voorhees T-shirt steps onto a ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

This is read by an automated voice. Please report any issues or inconsistencies here. Hungarian Nobel Prize laureate László Krasznahorkai delivered a rare lecture in Stockholm, presenting ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.